JP4991307B2 - 抗ｉｌ−２０抗体および結合パートナーならびに炎症において用いる方法 - Google Patents

抗ｉｌ−２０抗体および結合パートナーならびに炎症において用いる方法 Download PDF

Info

Publication number
JP4991307B2
JP4991307B2 JP2006541588A JP2006541588A JP4991307B2 JP 4991307 B2 JP4991307 B2 JP 4991307B2 JP 2006541588 A JP2006541588 A JP 2006541588A JP 2006541588 A JP2006541588 A JP 2006541588A JP 4991307 B2 JP4991307 B2 JP 4991307B2
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid residues
antibody
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2006541588A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007535490A5 (https=
JP2007535490A (ja
Inventor
ウェンフェン スー
ウェイン アール． キンズボゲル
チー チェン
スティーブン ディー． ヒューズ
ヤスミン エー． チャンドラセカー
ステイシー アール． ディロン
ジョイス エム． レーナー
アンソニー ダブリュー． シアダク
パラブール ブイ． シバクラマー
マーガレット ディー． ムーア
Original Assignee
ザイモジェネティクス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザイモジェネティクス， インコーポレイテッド filed Critical ザイモジェネティクス， インコーポレイテッド
Publication of JP2007535490A publication Critical patent/JP2007535490A/ja
Publication of JP2007535490A5 publication Critical patent/JP2007535490A5/ja
Application granted granted Critical
Publication of JP4991307B2 publication Critical patent/JP4991307B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2006541588A 2003-11-21 2004-11-19 抗ｉｌ−２０抗体および結合パートナーならびに炎症において用いる方法 Expired - Fee Related JP4991307B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US52413103P 2003-11-21 2003-11-21
US60/524,131 2003-11-21
US55585704P 2004-03-24 2004-03-24
US60/555,857 2004-03-24
PCT/US2004/039071 WO2005052000A2 (en) 2003-11-21 2004-11-19 Anti-il-20 antibodies and binding partners and methods of using in inflammation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011212399A Division JP2012036204A (ja) 2003-11-21 2011-09-28 抗ｉｌ−２０抗体および結合パートナーならびに炎症において用いる方法

Publications (3)

Publication Number Publication Date
JP2007535490A JP2007535490A (ja) 2007-12-06
JP2007535490A5 JP2007535490A5 (https=) 2011-03-03
JP4991307B2 true JP4991307B2 (ja) 2012-08-01

Family

ID=34636508

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2006541588A Expired - Fee Related JP4991307B2 (ja) 2003-11-21 2004-11-19 抗ｉｌ−２０抗体および結合パートナーならびに炎症において用いる方法
JP2006541597A Pending JP2007537993A (ja) 2003-11-21 2004-11-19 抗ｉｌ−２０受容体抗体および結合パートナーならびに炎症において用いる方法
JP2011212399A Pending JP2012036204A (ja) 2003-11-21 2011-09-28 抗ｉｌ−２０抗体および結合パートナーならびに炎症において用いる方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2006541597A Pending JP2007537993A (ja) 2003-11-21 2004-11-19 抗ｉｌ−２０受容体抗体および結合パートナーならびに炎症において用いる方法
JP2011212399A Pending JP2012036204A (ja) 2003-11-21 2011-09-28 抗ｉｌ−２０抗体および結合パートナーならびに炎症において用いる方法

Country Status (8)

Country Link
US (3) US20050170468A1 (https=)
EP (3) EP1697418A2 (https=)
JP (3) JP4991307B2 (https=)
AT (1) ATE447587T1 (https=)
CA (2) CA2542546A1 (https=)
DE (1) DE602004023965D1 (https=)
ES (1) ES2334140T3 (https=)
WO (2) WO2005052001A2 (https=)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5945511A (en) * 1997-02-20 1999-08-31 Zymogenetics, Inc. Class II cytokine receptor
US5965704A (en) * 1997-08-05 1999-10-12 Zymogenetics, Inc. Class two cytokine receptor-11
US6576743B1 (en) * 1997-11-26 2003-06-10 Zymogenetics, Inc. Mammalian cytokine-like polypeptide-10
US6610286B2 (en) * 1999-12-23 2003-08-26 Zymogenetics, Inc. Method for treating inflammation using soluble receptors to interleukin-20
US7122632B2 (en) * 1999-12-23 2006-10-17 Zymogenetics, Inc. Soluble Interleukin-20 receptor
DE60123998T2 (de) * 2000-08-08 2007-09-06 Zymogenetics, Inc., Seattle Lösliche zcyctor 11 cytokinrezeptoren
JP2007525438A (ja) * 2003-03-24 2007-09-06 ザイモジェネティクス， インコーポレイテッド 抗ｉｌ−２２ｒａ抗体および結合パートナー、ならびに炎症における使用法
AU2005299809B2 (en) * 2004-10-22 2010-12-02 Zymogenetics, Inc. Anti-IL-22RA antibodies and binding partners and methods of using in inflammation
EP1856156A2 (en) * 2005-02-08 2007-11-21 ZymoGenetics, Inc. Anti-il-20, anti-il-22 and anti-il-22ra antibodies and binding partners and methods of using in inflammation
US7611705B2 (en) * 2007-06-15 2009-11-03 National Cheng Kung University Anti-IL-20 antibody and its use in treating IL-20 associated inflammatory diseases
BRPI0914916A2 (pt) * 2008-06-30 2015-10-20 Novo Nordisk As anticorpos de interleucina-20 anti-humanos, assim como método de produção dos mesmos
US8012478B2 (en) * 2008-10-07 2011-09-06 National Cheng Kung University Use of anti-IL-20 antibody for treating stroke
JP5860699B2 (ja) * 2008-10-07 2016-02-16 ナショナル チェン クン ユニバーシティ 骨粗鬆症の治療のためのｉｌ−２０アンタゴニストの使用
US7837994B2 (en) * 2008-10-07 2010-11-23 National Cheng Kung University Use of anti-IL-20 antibody for treating osteoporosis
US8454956B2 (en) 2009-08-31 2013-06-04 National Cheng Kung University Methods for treating rheumatoid arthritis and osteoporosis with anti-IL-20 antibodies
CN103052403B (zh) * 2010-04-16 2014-10-22 成功大学 通过阻断il-20受体活性治疗与il-20受体介导的信号通路相关的病症
US8535674B2 (en) 2010-06-15 2013-09-17 National Cheng Kung University Treating breast cancer and inhibiting cancer-associated bone loss with anti-IL-20 antibody
WO2013117751A2 (en) 2012-02-10 2013-08-15 Novo Nordisk A/S Methods related to treatment of inflammatory diseases and disorders
WO2013164440A1 (en) 2012-05-03 2013-11-07 Novo Nordisk A/S Methods related to treatment of inflammatory diseases and disorders
WO2014006230A1 (en) * 2012-07-06 2014-01-09 Novo Nordisk A/S Il-20 epitopes and il-20 ligands
WO2014015133A1 (en) * 2012-07-19 2014-01-23 National Cheng Kung University Treatment of osteoarthritis using il-20 antagonists
US8852588B2 (en) * 2012-08-07 2014-10-07 National Cheng Kung University Treating allergic airway disorders using anti-IL-20 receptor antibodies
US8603470B1 (en) 2012-08-07 2013-12-10 National Cheng Kung University Use of IL-20 antagonists for treating liver diseases
WO2014093934A1 (en) * 2012-12-14 2014-06-19 Mindera Corporation Methods and devices for detection and acquisition of biomarkers
US20140314741A1 (en) * 2013-04-18 2014-10-23 Developmen Center For Biotechnology Human Antibody against Interleukin-20 and Treatment for Inflammatory Diseases
CN112961062A (zh) 2014-04-04 2021-06-15 沙特基础工业全球技术有限公司 最小化乙醇胺产物流股中的水含量
CN106164043A (zh) 2014-04-08 2016-11-23 沙特基础工业全球技术有限公司 最小化乙醇胺产物流股中的水含量
EP3148965A1 (en) 2014-05-27 2017-04-05 SABIC Global Technologies B.V. Production of tea 85% directly without blending with pure cut of dea 99%
CN106414395A (zh) 2014-05-30 2017-02-15 沙特基础工业全球技术有限公司 通过降低三乙醇胺塔处的温度改善乙醇胺产物流的质量和颜色
PE20170441A1 (es) 2014-06-06 2017-04-26 Bristol Myers Squibb Co Anticuerpos contra el receptor del factor de necrosis tumoral inducido por glucocorticoides (gitr) y sus usos
JP2017527262A (ja) * 2014-07-03 2017-09-21 イムノキュア アーゲーＩｍｍｕｎｏｑｕｒｅ Ａｇ ヒト由来抗ｉｌ−２０抗体および抗サイトカイン抗体同定アッセイ
MX2017015260A (es) 2015-06-03 2018-02-19 Squibb Bristol Myers Co Anticuerpos anti receptor de factor de necrosis tumoral inducible por glucocorticoide (gitr) para diagnostico del cancer.
AU2016356780A1 (en) 2015-11-19 2018-06-28 Bristol-Myers Squibb Company Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof
WO2017202813A1 (en) * 2016-05-24 2017-11-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of pulmonary bacterial infections
US9982043B2 (en) 2016-06-03 2018-05-29 National Cheng Kung University Use of IL-20 antagonists for treating pancreatic cancer
US20180057564A1 (en) * 2016-08-23 2018-03-01 Clover Biopharmaceuticals Antagonists of il-20 family of cytokines and their use
EP3615570A4 (en) 2017-04-25 2021-02-24 LBL Biotechnology Inc. USE OF IL-20 ANTAGONISTS FOR TREATMENT OF EYE DISEASES
CN110869392A (zh) 2017-05-16 2020-03-06 百时美施贵宝公司 用抗gitr激动性抗体治疗癌症
JP7258329B2 (ja) * 2018-09-01 2023-04-17 国立大学法人神戸大学 連続式振動流バッフル反応装置及び反応法
JP7588139B2 (ja) 2019-09-04 2024-11-21 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） 慢性閉塞性肺疾患の急性増悪の処置のためのｉｌ２０－ｒｂに特異的な抗体及びその使用

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208021A (en) * 1987-10-05 1993-05-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of preparing diphtheria immunotoxins
US5567584A (en) * 1988-01-22 1996-10-22 Zymogenetics, Inc. Methods of using biologically active dimerized polypeptide fusions to detect PDGF
US20020099179A1 (en) * 1989-12-21 2002-07-25 Linda K. Jolliffe Cdr-grafted antibodies
US5436155A (en) 1991-12-31 1995-07-25 Arch Development Corporation Isolated DNA encoding a somatostatin receptor
US5789192A (en) 1992-12-10 1998-08-04 Schering Corporation Mammalian receptors for interleukin-10 (IL-10)
GB2315386B (en) 1996-07-13 2000-10-18 Motorola Ltd Improved flow control in cellular radio networks
US5985614A (en) * 1996-08-30 1999-11-16 Human Genome Sciences, Inc. Polynucleotides encoding interleukin-19
EP2065396A1 (en) 1996-08-30 2009-06-03 Human Genome Sciences, Inc. Interleukin-19
DE19650541C2 (de) 1996-12-05 1999-05-12 Siemens Ag Verfahren zur Ermittlung eines ersten Referenzschriftzugs anhand mehrerer Musterschriftzüge
US5945511A (en) 1997-02-20 1999-08-31 Zymogenetics, Inc. Class II cytokine receptor
WO2000078961A1 (en) 1999-06-23 2000-12-28 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP0979102A4 (en) * 1997-04-30 2005-11-23 Enzon Inc DETAILED POLYPEPTIDE MODIFIED BY POLYALKYLENE OXIDE
US6486301B1 (en) 1997-07-16 2002-11-26 Human Genome Sciences, Inc. Interleukin-20
JP2001510035A (ja) 1997-07-16 2001-07-31 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド インターロイキン−２０
US5965704A (en) 1997-08-05 1999-10-12 Zymogenetics, Inc. Class two cytokine receptor-11
WO1999007740A2 (en) 1997-08-06 1999-02-18 Zymogenetics, Inc. Lipocalin homologs
IL136076A0 (en) * 1997-11-26 2001-05-20 Zymogenetics Inc Mammalian cytokin-like polypeptide -10
US6576743B1 (en) * 1997-11-26 2003-06-10 Zymogenetics, Inc. Mammalian cytokine-like polypeptide-10
EP1047781B1 (en) 1998-01-23 2004-07-28 Immunex Corporation Il-18 receptors
WO1999046379A2 (en) 1998-03-09 1999-09-16 Schering Corporation Human receptor proteins; related reagents and methods
US6586228B1 (en) 1998-03-09 2003-07-01 Schering Corporation Polynucleotides encoding DIRS1
ES2312205T3 (es) 1998-03-10 2009-02-16 Genentech, Inc. Nuevo polipeptido y acidos nucleicos que lo codifican.
US6982320B2 (en) 1998-03-19 2006-01-03 Human Genome Sciences, Inc. Cytokine receptor common gamma chain like
AU5203199A (en) 1998-05-26 1999-12-13 Procter & Gamble Company, The Chimeric molecules comprising an extracellular ligand binding domain of a receptor and an ige fc or constant region, and their use in an assay system
NZ531664A (en) 1998-09-01 2005-07-29 Genentech Inc Pro1317 polypeptides and sequences thereof with homology to the semaphorin B glycoprotein family
ES2221759T3 (es) 1998-11-25 2005-01-01 Zymogenetics, Inc. Zace1: una metaloenzima humana.
EP1141008A1 (en) 1998-12-31 2001-10-10 Millennium Pharmaceuticals, Inc. Class ii cytokine receptor-like proteins and nucleic acids encoding them
AU5047600A (en) 1999-05-27 2000-12-18 Schering Corporation Mammalian interleukin-10 homologs: il-d110 and il-d210
AU2253301A (en) 1999-12-03 2001-06-12 Zymogenetics Inc. Human cytokine receptor
EP1244708B8 (en) * 1999-12-23 2007-03-07 ZymoGenetics, Inc. Method for treating inflammation
US6610286B2 (en) 1999-12-23 2003-08-26 Zymogenetics, Inc. Method for treating inflammation using soluble receptors to interleukin-20
DE60123998T2 (de) 2000-08-08 2007-09-06 Zymogenetics, Inc., Seattle Lösliche zcyctor 11 cytokinrezeptoren
ATE333888T1 (de) * 2000-09-15 2006-08-15 Zymogenetics Inc Verwendung eines polypeptids, welches die extrazelluläre domäne von il-20ra und il-20rb enthält, zur behandlung von entzündungen
EP1390060A2 (en) 2001-01-26 2004-02-25 Eli Lilly And Company Use of lp82 to treat body weight disorders
CA2433933A1 (en) 2001-02-28 2002-09-12 Eli Lilly And Company Use of lp82 to treat hematopoietic disorders
EP1399472B1 (en) 2001-03-09 2009-06-03 ZymoGenetics, Inc. Soluble heterodimeric cytokine receptor
DE10154579A1 (de) 2001-11-07 2003-05-28 Medigene Ag Topikale Verwendung von Cytokinen und Chemokinen zur Behandlung von viralen oder mykotischen Hauterkrankungen oder Tumorerkrankungen
CA2467723C (en) 2001-12-17 2011-09-27 Zymogenetics, Inc. Method for treating cervical cancer
AU2003223344B9 (en) 2002-03-22 2009-07-16 Zymogenetics, Inc. Anti-IL-TIF antibodies and methods of using in inflammation
JP2004121218A (ja) * 2002-08-06 2004-04-22 Jenokkusu Soyaku Kenkyusho:Kk 気管支喘息または慢性閉塞性肺疾患の検査方法
JP4053444B2 (ja) * 2003-03-07 2008-02-27 シャープ株式会社 携帯可能な多機能電子機器
JP2007525438A (ja) * 2003-03-24 2007-09-06 ザイモジェネティクス， インコーポレイテッド 抗ｉｌ−２２ｒａ抗体および結合パートナー、ならびに炎症における使用法
AU2005299809B2 (en) * 2004-10-22 2010-12-02 Zymogenetics, Inc. Anti-IL-22RA antibodies and binding partners and methods of using in inflammation
JP2008106946A (ja) * 2005-02-10 2008-05-08 Matsushita Electric Ind Co Ltd 冷凍サイクル装置
JP2010502224A (ja) * 2006-09-08 2010-01-28 アボット・ラボラトリーズ インターロイキン１３結合タンパク質
BRPI0914916A2 (pt) * 2008-06-30 2015-10-20 Novo Nordisk As anticorpos de interleucina-20 anti-humanos, assim como método de produção dos mesmos

Also Published As

Publication number Publication date
WO2005052001A3 (en) 2005-08-04
US7393684B2 (en) 2008-07-01
EP2143733A1 (en) 2010-01-13
DE602004023965D1 (de) 2009-12-17
EP1692180A2 (en) 2006-08-23
US20080247945A1 (en) 2008-10-09
US20050136004A1 (en) 2005-06-23
EP1697418A2 (en) 2006-09-06
ES2334140T3 (es) 2010-03-05
CA2545867A1 (en) 2005-06-09
WO2005052000A3 (en) 2005-10-27
JP2007537993A (ja) 2007-12-27
CA2542546A1 (en) 2005-06-09
JP2012036204A (ja) 2012-02-23
EP1692180B1 (en) 2009-11-04
US20050170468A1 (en) 2005-08-04
ATE447587T1 (de) 2009-11-15
JP2007535490A (ja) 2007-12-06
WO2005052001A2 (en) 2005-06-09
WO2005052000A2 (en) 2005-06-09
US8907068B2 (en) 2014-12-09

Similar Documents

Publication Publication Date Title
JP4991307B2 (ja) 抗ｉｌ−２０抗体および結合パートナーならびに炎症において用いる方法
EP1606317B1 (en) Anti-il-22ra antibodies and binding partners and methods of using in inflammation
US8124088B2 (en) Methods of treatment using anti-IL-22RA antibodies
US20100111960A1 (en) Anti-il-20, anti-il-22 and anti-il-22ra antibodies and binding partners and methods of using in inflammation
JP2008509227A (ja) 可溶性ＺｃｙｔｏＲ１４、抗ＺｃｙｔｏＲ１４抗体および結合相手ならびに炎症における使用方法
CN1798768B (zh) 抗il-22ra抗体和结合伴侣及其应用
HK1173453A (en) Anti-il-22ra antibodies and binding partners and methods of using in inflammation
HK1110333B (en) Anti-il-22ra antibodies and binding partners and methods of using in inflammation

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20071016

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100715

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20101014

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20101021

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110117

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20110117

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110328

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110627

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110704

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110928

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120305

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120403

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120411

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120507

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150511

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees